Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | TXN | P10599 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31175737 | 1.00 | BCHE (0.73) | BCHERAB9ANPC1TXNSMN1; SMN2 | |
| Bromide SCHEMBL29546581 | 0.98 | BCHE (0.71) | BCHERAB9ANPC1TXNSMN1; SMN2 | |
| Bromide SCHEMBL2506425 | 0.98 | BCHE (0.71) | BCHERAB9ANPC1TXNSMN1; SMN2 | |
| SCHEMBL8098342 | 0.86 | RAB9A (0.82) | BCHERAB9ANPC1TXNSMN1; SMN2 | |
| SCHEMBL11475158 | 0.85 | BCHE (1.00) | BCHERAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL425175 | 0.83 | RAB9A (1.00) | BCHERAB9ANPC1TXNSMN1; SMN2 | |
| SCHEMBL22292431 | 0.82 | BCHE (0.69) | BCHERAB9ANPC1TXNSMN1; SMN2 | |
| SCHEMBL11307167 | 0.82 | TXN (1.00) | BCHERAB9ANPC1TXNSMN1; SMN2 | |
| SCHEMBL8425964 | 0.82 | SMN1; SMN2 (0.79) | BCHERAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL2948524 | 0.82 | RAB9A (0.91) | BCHERAB9ANPC1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| CN-109659546-B | Sulfur/nitrogen/silicon co-doped graphite composite negative electrode material and preparation method thereof | 成都爱敏特新能源技术有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-110845910-A | OLED ink for ink-jet printing and preparation method thereof | 成都新柯力化工科技有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-108101935-A | Silane of one kind structure containing benzimidazole and preparation method thereof | 烟台大学 | 2018-06-01 | — | — | CN | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4541352-A3 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | Algernon Pharmaceuticals Inc. (CA) | 2025-07-16 | — | — | EP | disclosed |
| EP-4541352-A2 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | Algernon Pharmaceuticals Inc. (CA) | 2025-04-23 | — | — | EP | disclosed |
| EP-4541352-A2 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | Algernon Pharmaceuticals Inc. (CA) | 2025-04-23 | — | — | EP | disclosed |
| US-12280026-B2 | Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease | ALGERNON PHARMACEUTICALS INC. (CA) | 2025-04-22 | — | — | US | disclosed |
| US-12280026-B2 | Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease | ALGERNON PHARMACEUTICALS INC. (CA) | 2025-04-22 | — | — | US | disclosed |
| EP-3923938-B1 | IFENPRODIL OR RADIPRODIL FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | SEYLTX INC (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-2110416-A2 | Dispersion of water-insoluble colorant, method of producing substance containing water-insoluble colorant, fine particles of water-insoluble colorant, dispersing agent for water-insoluble colorant, and recording liquid, ink set, printed article, method of forming image and image forming apparatus using the same | Fujifilm Corporation (JP) | 2009-10-21 | — | — | EP | disclosed |
| US-20090246481-A1 | DISPERSION OF WATER-INSOLUBLE COLORANT, METHOD OF PRODUCING SUBSTANCE CONTAINING WATER-INSOLUBLE COLORANT, FINE PARTICLES OF WATER-INSOLUBLE COLORANT, DISPERSING AGENT FOR WATER-INSOLUBLE COLORANT, AND RECORDING LIQUID, INK SET, PRINTED ARTICLE, METHOD OF FORMING IMAGE AND IMAGE FORMING APPARATUS USING THE SAME | FUJIFILM CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090246481-A1 | DISPERSION OF WATER-INSOLUBLE COLORANT, METHOD OF PRODUCING SUBSTANCE CONTAINING WATER-INSOLUBLE COLORANT, FINE PARTICLES OF WATER-INSOLUBLE COLORANT, DISPERSING AGENT FOR WATER-INSOLUBLE COLORANT, AND RECORDING LIQUID, INK SET, PRINTED ARTICLE, METHOD OF FORMING IMAGE AND IMAGE FORMING APPARATUS USING THE SAME | FUJIFILM CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090214797-A1 | INKJET INK COMPOSITION, AND INKJET RECORDING METHOD AND PRINTED MATERIAL EMPLOYING SAME | FUJIFILM CORPORATION (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090214797-A1 | INKJET INK COMPOSITION, AND INKJET RECORDING METHOD AND PRINTED MATERIAL EMPLOYING SAME | FUJIFILM CORPORATION (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | BCHE 3701/4885RAB9A 3136/4885NPC1 1285/4885 |
| US-12280026-B2 | Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease | INMT, RNMT, MMP1 | BCHE 115/4885RAB9A 561/4885NPC1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.